F
Fabio A.B. Schutz
Researcher at Harvard University
Publications - 86
Citations - 9410
Fabio A.B. Schutz is an academic researcher from Harvard University. The author has contributed to research in topics: Cancer & Prostate cancer. The author has an hindex of 29, co-authored 81 publications receiving 7604 citations. Previous affiliations of Fabio A.B. Schutz include Niigata University & Brigham and Women's Hospital.
Papers
More filters
Journal ArticleDOI
Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens
Joaquim Bellmunt,Toni K. Choueiri,Ronan Fougeray,Fabio A.B. Schutz,Yacine Salhi,Eric Winquist,Stéphane Culine,Hans von der Maase,David J. Vaughn,Jonathan E. Rosenberg +9 more
TL;DR: A scoring system that classifies patients with platinum-refractory disease on second-line chemotherapy into four risk groups with different outcome is developed and similar to the first-line setting, the presence of visceral metastases and poor PS predict a worse prognosis.
Journal ArticleDOI
Congestive Heart Failure Risk in Patients With Breast Cancer Treated With Bevacizumab
Toni K. Choueiri,Erica L. Mayer,Youjin Je,Jonathan E. Rosenberg,Paul L. Nguyen,Georges Azzi,Joaquim Bellmunt,Harold J. Burstein,Fabio A.B. Schutz +8 more
TL;DR: This is the first comprehensive report to show that bevacizumab is associated with an increased risk of significant heart failure in patients with breast cancer.
Journal ArticleDOI
Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials
TL;DR: Treatment with the VEGFR tyrosine-kinase inhibitors sunitinib and sorafenib is associated with a significant increase in risk of bleeding.
Journal ArticleDOI
Meta-Analysis of Randomized Controlled Trials for the Incidence and Risk of Treatment-Related Mortality in Patients With Cancer Treated With Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors
TL;DR: In a meta-analysis of RCTs, the use of VEGFR TKIs was associated with an increased risk of FAEs compared with control patients.
Journal ArticleDOI
Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.
Robert J. Motzer,Bernard Escudier,Saby George,Hans J. Hammers,Sandhya Srinivas,Scott S. Tykodi,Jeffrey A. Sosman,Elizabeth R. Plimack,Giuseppe Procopio,David F. McDermott,Daniel Castellano,Toni K. Choueiri,Frede Donskov,Howard Gurney,Stéphane Oudard,Martin Eduardo Richardet,Katriina Peltola,Ajjai Alva,Michael A. Carducci,John Wagstaff,Christine Chevreau,Satoshi Fukasawa,Yoshihiko Tomita,Thomas Gauler,Christian Kollmannsberger,Fabio A.B. Schutz,James Larkin,David Cella,M. Brent McHenry,Shruti Shally Saggi,Nizar M. Tannir +30 more
TL;DR: Nivolumab continues to be better than everolimus in extending the lives of patients, providing a long-lasting response to treatment, and improving quality of life with a manageable safety profile, and this supports the long-term benefits of nivolumsab monotherapy in patients with previously treated aRCC.